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Abstract 
Transglutaminase 2 (TG2) is a multifunctional protein with diverse catalytic activities and biological roles. Its 
best studied function is the Ca
2+
-dependent transamidase activity leading to formation of γ-glutamyl-ε-lysine 
isopeptide crosslinks between proteins or γ-glutamyl-amine derivatives. TG2 has a poorly studied isopeptidase 
activity cleaving these bonds. We have developed and characterised TG2 mutants which are significantly 
deficient in transamidase activity while have normal or increased isopeptidase activity (W332F) and vice versa 
(W278F). The W332F mutation led to significant changes of both the Km and the Vmax kinetic parameters of the 
isopeptidase reaction of TG2 while its calcium and GTP sensitivity was similar to the wild type enzyme. The 
W278F mutation resulted in six times elevated amine incorporating transamidase activity demonstrating the 
regulatory significance of W278 and W332 in TG2 and that mutations can change opposed activities located at 
the same active site. The further application of our results in cellular systems may help to understand TG2 driven 
physiological and pathological processes better and lead to novel therapeutic approaches where an increased 
amount of cross-linked proteins correlates with the manifestation of degenerative disorders. 
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Introduction 
 
Transglutaminase 2 (TG2; tissue transglutaminase) is a moonlighting protein with transglutaminase, GTPase, 
ATPase, protein disulphide isomerase, protein kinase catalytic activities and its functions have been implicated 
in various biological processes as a catalytically active or an interacting protein partner (Eckert et al. 2013, Wang 
Z and Griffin M 2013, Iismaa et al. 2009). It is a member of an enzyme family with 7 catalytically active and one 
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inactive additional members; their generally known catalytic activity is calcium-dependent protein crosslinking 
to form highly resistant N
ε
 -(γ-glutamyl)lysine bond between proteins (Lorand and Graham 2003) which has 
significant roles in physiological and pathological processes, such as blood coagulation, cornification, apoptosis, 
extracellular matrix stabilization and insoluble aggregate formation in neurodegenerative diseases or fibrotic 
disorders. Mono- or polyaminylation of glutamine residues of proteins by a transglutaminase occurs in the 
presence of different amines instead of lysine residues of proteins providing important physiological regulation 
including the activation of insulin secretion by serotonylation of the Rab small GTPase (Paulmann et al. 2009), 
and histamine incorporation into fibrinogen (Lai and Greenberg 2013) or gliadin peptides (Qiao et al. 2005) 
which potentially modulate inflammatory processes. In the absence of any amine donor substrate deamidation of 
the glutamine residue takes place leading to, for example, a more potent antigen in celiac disease (Shan et al. 
2002). The incorporation of a peptide or biogenic amine and deamidation or polyamine linkage modify charges 
in the target proteins switching on or off the biological process in which they participate. 
The transamidation reaction creates proteinase resistant bonds and so far the existence of a specific 
enzyme which can split these isopeptide bonds in proteins have not been reported. The proteins crosslinked by 
transamidation are degraded by the proteasomal system or in lysosomes by proteases but they do not touch the 
isopeptide bond (Guilluy et al. 2007.). Fibrinolysis is responsible for digestion of the highly crosslinked blood 
clot containing many isopeptide bonds but  the N
ε
 -(γ-glutamyl)lysine bond is itself not split and the released ε -
(γ-glutamyl)lysine isodipeptide is detectable in the circulation (Tarcsa and Fesus 1990). There is an enzyme, γ-
glutamilamine cyclotransferase which is able to cleave the N
ε
 -(γ-glutamyl)lysine bond in the dipeptide but this 
enzyme has significant activity only in the kidney and in the intestine (Raczynski et al. 1975).  
It was reported that Factor XIIIa, a member of the transglutaminase family, can reverse crosslinking of 
α2-plasmin inhibitor to fibrinogen and fibrin potentially regulating the fibrinolytic processes (Ichinose and Aoki 
1982; Mimuro et al. 1986). Based on the kinetic and mechanistic similarities to papain it has been proposed that 
transglutaminases could play a dynamic role in breaking of N
ε
-(γ-glutamyl)lysine isopeptide bonds 
(Parameswaran et al. 1997). As a confirmation, the release of a cadaverine linked quencher from oligopeptides 
by guinea pig liver (gpTG2) and human red blood cell transglutaminases could be shown (Parameswaran et al. 
1997, Folk et al. 1967). This data has raised the possibility of the existence of a still unknown regulatory system 
which can switch on or off transamidase and isopeptidase activities of transglutaminases separately. An enzyme 
with isopeptidase activity disconnected from transamidation may have particular use in conditions with increased 
intracellular TG2 activity leading to accumulation of crosslinked proteins in intraneuronal inclusions in multiple 
neurodegenerative diseases (Martin et al. 2013) or in tissue fibrosis affecting different organs (Johnson et al. 
2007). Treatment with specific transglutaminase inhibitors can slow down or stop these pathological unwanted 
processes but they are not able to reverse them. The development of special inhibitors which are able to block 
only the transamidase activity of transglutaminases or the potential application of a protein which has enhanced 
or only isopeptidase activity could provide an alternative way to decrease the load of crosslinked proteins. 
However, disconnection of the isopeptidase and transamidase activities of any transglutaminase has not been 
demonstrated so far. 
In this study we made an attempt to separate the isopeptidase and transamidase activities of TG2 by site 
directed mutagenesis. Based on the analysis of published x-ray structures we changed amino acids which are 
located around the substrate binding cleft and are particularly responsible for the formation of the hydrophobic 
3 
 
tunnel and the stabilisation of the transition state during the transglutaminase reaction process. Two special 
mutants were found and characterised, one deficient in transamidase activity with higher isopeptidase activity 
and another with opposite properties. Based on our study the potential biological application of modified 
transglutaminases can be considered.  
 
Materials and methods 
 
Materials 
All materials were purchased from Sigma (St Louis, MO, USA) unless otherwise indicated. 
 
Transglutaminase enzyme preparations 
For more than two decades most of the studies in the transglutaminase field used the cDNA of TG2 cloned by 
Gentile et al. (1991) which contains Gly at amino acid position 224. We also used this Gly
224
 containing clone in 
our previous works and at the beginning of this study. However, subsequent analysis of large genomic databases 
revealed that all the so far sequenced human TG2 alleles have Val at amino acid position 224. The detailed 
comparison of Val and Gly containing variants has demonstrated significant difference in their calcium binding 
affinity and sensitivity affecting both in vitro and in situ transglutaminase activity assays (Kiraly et al. 2013; 
Kanchan et al. 2013). Based on this data we have decided during the course of this study to change Gly back to 
Val at position 224 in our TG2 constructs. 
The earlier prepared Gly
224
 containing recombinant human TG2 variant and its mutants were expressed 
in N-terminally (His)6-tagged form (pET-30 Ek/LIC-TG2) and purified by Ni-NTA affinity chromatography as 
described previously (Király et al. 2009). There were no differences in expression level, yield and stability of the 
mutant proteins as compared to the wild type TG2. After introducing the Val
224
 TG2 the expression and 
purification protocol was refined and for the comparative studies of the two variants and their mutants the 
following improved protocol was applied: After transformation Rosetta 2 strains were grown in LB broth at 
25°C to an OD600 0.6 to 0.8. To induce the expression of His-tagged proteins, the cultures were grown 
overnight at 16°C in the presence of 0.05 mmol/L isopropyl β-D-thiogalactoside. The cells were harvested by 
centrifugation at 4°C and then resuspended in 25 ml per litre of culture of ice cold binding buffer (50 mM Tris-
HCl, pH 7.2, 1 mM EDTA, 5 mM imidazole) with 1 mM PMSF. After cell lysis by sonication (6 times 30 
seconds with 1 minute breaks, on ice), and centrifugation (20000g, 30 minutes, 4°C) the His-tagged protein 
containing supernatant was loaded onto an equilibrated (20 ml binding buffer without DTT and then 10 ml 
binding buffer) His GraviTrap column (GE Healthcare, Little Chalfont, UK). After loading, the column was 
washed with 10 ml binding buffer, then 10 ml binding buffer with 20 mM imidazole. Finally, the protein was 
eluted by 10 ml of 500 mM imidazole in binding buffer and the eluate was concentrated using Amicon 
Centricon-YM 50 MW (Millipore, Billerica, MA). Then the buffer was exchanged to 20 mM Tris-HCl, pH 7.2, 
with 150 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, and 10% by volume glycerol. The protein concentration 
was determined by the Bradford method (Bio-Rad, München, Germany). Finally, protein purity was checked by 
Coomassie BB staining of SDS-polyacrylamide gels and by Western blots. 
 
End point transamidase activity assay based on labelled amine incorporation on microtiter plate 
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The classical microtiter plate assay based on the incorporation of 5-(biotinamido)pentylamine (Zedira) into 
immobilised N,N-dimethylated casein (DMC) was used as described before (Madi et al. 1998) with the 
following modifications. The total volume of reaction mixture was 200 μl containing 10 mM dithiothreitol 
(DTT), 1 mM N-(5-aminopentyl)biotinamide, 5 mM CaCl2, 0.5 µg TG2 in 0.1 M Tris-HCl buffer, pH 8.5. The 
reaction was started with addition of 50 µl enzyme solution and performed at 37°C for 30 minutes. The cross 
linked product was detected by streptavidine-alkaline phosphatase and quantitated at 405 nm by the addition of 
p-nitro-phenyl phosphate.  
 
End point transamidase activity assay based on labelled glutamine donor peptide incorporation on microtiter 
plate 
Another microtiter plate assay was also used to provide the substrates in other orientation. The commercial 
CovTest (CovalAb, France) is able to measure specifically the transamidase activity of TG2. The basis of the 
assay is the incorporation of a short biotinylated peptide (biotin-pepT26, acyl-donor) into spermine (acyl-
acceptor) which was covalently coupled to the surface of the activated plate. We performed the assay based on 
the article in which the assay was described (Perez et al. 2009). The original plates were ordered from CovalAb 
and washed with washing solution containing 0.1 % Tween-20 in 0.1M Tris-HCl, pH 8.5 at 37°C for 15 minutes. 
Then 50 μl of cold reaction mixture containing 20 mM biotin-pepT26 oligopeptide (CovalAb), 30 mM CaCl2, 10 
mM DTT in reaction buffer (150 mM NaCl, 40 mM Tris-HCl, pH 8.3) were loaded into the well. The reaction 
was started by addition of 60 μl sample (0.5 μg protein) and was incubated at 37°C for 25 minutes. Next, after 
washing 3 times 110 μl/well freshly prepared ExtrAvidin peroxidase solution (dilution: 1/5000 in washing buffer 
containing 1 % BSA) was added and incubated for 15 minutes at 37°C. After washing again 3 times 100 μl TMB 
substrate (freshly prepared from TMB tablet using 200 μl DMSO to resolve the tablet and then it was completed 
by 9.8 ml phosphate-citrate buffer, pH 5.0 containing 10 μl 30 % H2O2) was added in each well. The colour 
reaction was stopped with 50 μl 2.5N H2SO4 and absorbances were read at 450 nm. 
 
Fluorescence isopeptidase assay using Zedira substrates 
Transglutaminase cleaves the isopeptide bond in the synthesised substrate releasing the dark quencher (2,4-
dinitrophenyl) linked to the cadaverine spacer following the increase of fluorescence from the N-terminally 
attached fluorophore 2-aminobenzoyl (2-Abz). Based on the suggested protocol the final concentrations in the 
reaction mixture were: 50 mM Tris-HCl, 10 mM CaCl2, 100 mM NaCl, 0.1 % (w/v) PEG6000, 50 μM 
A102/A101 and 2.8 mM DTT (added with the starting solution which contained the enzyme). The reaction was 
monitored at 37°C by a BIOTEK Synergy 4 or H1 multiple reader (Ex/Em: 318/413 nm). After subsequent 
optimisation the isopeptidase assay was performed at pH 6.8 and in the absence of H-Gly-OMe, because it did 
not have a significant effect on the isopeptidase activity (data not shown). For the analysis of pH dependence 50 
mM MOPS-NaOH based buffer was applied. 
 
Kinetic transamidase assay 
The kinetic transamidase assay was performed with slight modification of a previously published procedure 
(Lorand et al. 1998): The reaction mixture contained 50 mM Tris-HCl buffer pH 7.5, 0.5 mM dansyl-cadaverine, 
2 mg/ml N,N’-dimethylated casein, 1 mM DTT, and CaCl2 or 10 mM EDTA. The reaction volume was 100 μl 
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and the assay was started with the addition of 20 μl enzyme (100 nM TG2 final concentration). The activity was 
calculated based on the linear part of the increasing fluorescence (Ex/Em: 360/490 nm; at 37°C). 
 
BODIPY-GTPγS nucleotide binding assay 
500 nM BODIPY-GTPγS (Invitrogen; McEwen et al. 2001) GTP analog was used to measure nucleotide binding 
to increasing amounts of TG2 proteins in the presence of 20 mm HEPES pH 7.5, 150 mM NaCl, 0.1 TCEP, 0.05 
% Tween-20, 0.1 mM EGTA, 1 mM MgCl2. 
 
Results and discussion 
 
1. In silico considerations for the separation of transamidase and isopeptidase activity of TG2 
Comparing the known crystal structures of human transglutaminases with corresponding papain structures 
reveals isolation of the active site of both from ambient water by being buried in the core domain, and 
surrounded by bulky hydrophobic residues (Pinkas et al. 2007, Chica et al. 2004, Iismaa et al. 2003, Murthy et 
al. 2002). Although space-filling models in the presence of substrate (inhibitor) show the active site quite 
exposed to water, in the absence of substrate the water is repelled from the catalytic cavity by hydrophobic 
tunnels isolated by annealing hydrophobic side chains, such as W241-W332, W278-F334. Also, W180, W337 
and Y510 shield the active site from the intrusion of water. In silico modeling of TG2 suggested that suppressive 
replacements of one or two of these seven residues would make the catalytic core “leaky” to the solvent water 
molecules without disrupting secondary domain structures. The enhanced access of ambient water to the 
catalytic site was expected to divert transglutaminase activity towards hydrolysis of the transglutaminase 
reaction products. To prevent the disruption of the active site we designed the modification to save the 
hydrophobic character of this site by using amino acids with shorter side chains. Based on this consideration we 
designed 12 single mutants namely: W180F, W180L, W241F, W241L, W278F, W278L, W332F, W332L, 
F334L, W337F, W337L, Y516L. These mutants in human TG2 have not yet been purposefully created for the 
characterisation of their isopeptidase property (Murthy et al. 2002, Iismaa et al. 2003).  
 
 
2. Effect of changing hydrophobic amino acids around the active site of TG2 on its isopeptidase and 
transamidase activity  
At the beginning of this study the mutants designed above were constructed by site directed mutagenesis in the 
plasmid clone of the Gly
224
 containing TG2 variant, since this clone had been used for many studies by different 
laboratories in the transglutaminase research field until Kanchan et al. (2013) provided data about biochemical 
differences between Val
224
 and Gly
224
 containing variants. To examine the effect of hydrophobic amino acids on 
transglutaminase activities single mutants of TG2 Gly
224
 were tested for both isopeptidase and transamidase 
activities (Fig. 1). Most of these mutants lost both transglutaminase activities, particularly in case of changing 
Trp to Leu while an Y516L change did not affect them significantly. W337F and W180F mutations resulted in 
approximately 15-20 % transamidase activities but W180F mutant lost totally its isopeptidase activity. The 
exchange of Trp
332
 to Phe and Trp
278
 to Phe resulted in mutants having only either isopeptidase or transamidase 
activity, respectively. The W278F mutant showed only 7% remnant isopeptidase activity. Some double mutants 
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were also constructed but these did not lead to better separation of isopeptidase and transamidase activities, 
though the significantly decreased transamidase activity of W337F mutant was compensated by its combination 
with Y516L exchange. 
In earlier studies with rat TG2 only changing Trp
241
 resulted in significant decrease of transamidase 
activity (Murthy et al. 2002). In case of human TG2 not only the hydrophobicity of the amino acids around the 
active site and in the substrate binding area plays a role during the reaction catalysis, but the complexity of the 
surrounding Trp-s (space filling property, aromatic carbon atom ring containing nitrogen) also have important 
effect on stabilisation of the transition states of transglutaminase activities (recently reviewed by Keillor et al. 
2014). Pinkas et al. (2007) reported that the W332A mutation in human TG2 and the W332F mutation in rat TG2 
lead to loss or lower transamidase activity, respectively (Murthy et al. 2002), but in these articles only the 
transamidase activity was tested. The demonstrated functional difference between orthologous TG2 enzymes 
also makes comparison difficult (Ruan et al. 2008). A related report came from Keillor’s laboratory (2008) after 
they performed random mutagenesis in gpTG2 targeting selected amino acids around the active site to find 
special mutants which can form the amide bond in a specific, efficient and economical way. They identified 
Trp
332
 which when replaced by Phe or Tyr conferred very low transamidation activity on the enzyme. However, 
this study did not target Trp
278
 (W278F). Although our obtained results partially refuted our initial predictions 
that shorter hydrophobic residues around the active site result in increases of isopeptidase activity, because the 
W278F mutant lost its isopeptidase and kept its transamidase activity, these demonstrated that the separation and 
independent regulation of the different type of transglutaminase activities was possible and there was no 
correlation between transamidase and isopeptidase activities.  
 
 
3. Characterisation of transglutaminase mutants with dominant isopeptidase or transamidase activity  
To evaluate the effect of the mutated amino acids on catalytic activities of the wild type human TG2, Gly
224
 was 
changed to Val
224
 in case of W332F, W278F, W241F and C277S TG2 mutants (the last two served as controls). 
(Fig. 2 and Fig. 3). In the isopeptidase assay Val
224
 containing WT TG2 showed 70% higher while the W332F 
and W278F mutants twofold higher activity than their Gly
224
 counterpart (Fig. 2). Val
224
 W332F TG2 presented 
1.5 times while Gly
224
 W332F TG2 1.3 times higher isopeptidase activity than the Val
224
 or Gly
224
 WT TG2 
variants, respectively, but in case of the W278F variants these ratios were 0.33 and 0.18. In case of the control 
W241F (conserved Trp) and C277S (active site) mutants the Gly to Val exchange did not show detectable 
modification of their isopeptidase activity. 
In an end-point transamidase activity assay Val
224
 WT TG2 exhibited 33% increases and both W332F 
and W278F mutants showed slightly higher activity than their Gly
224
 variants. Using a kinetic transamidase assay 
we also observed that Val
224
 variants have higher activities; Val
224 
WT TG2 exhibited a two fold increase 
compared to Gly
224
 WT TG2. Surprisingly, in this kinetic transamidase assay both variants of the W278F mutant 
presented significantly increased, 5.8 times higher activities compared to the appropriate WT TG2 variants. 
Using the kinetic assay the percentage of remaining transamidase activity in case of Val
224
 and Gly
224
 W332F 
mutants compared to the appropriate WT variant were higher (47% and 73%, respectively) than in the end-point 
assay (18% and 7%, respectively). The Gly
224
 variant of the W241F control mutant, which showed only very low 
transamidase activity in the kinetic assay, was 4 times more active in the Val
224
 containing form confirming the 
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structural significance of amino acid position 224 in TG2 (Kanchan et al. 2013). The C277S variants were totally 
inactive in all activity measurements (data not shown). 
Taken together the Val
224
 containing enzymes demonstrated consequently higher isopeptidase and 
transamidase activities compared to their Gly
224
 variants. Therefore, we decided to use the Val
224
 TG2s for 
further characterisations labelling them as TG2 WT (no mutation), TG2-I (W332F, isopeptidase active and 
transamidase deficient) and TG2-T (W278F, transamidase active and isopeptidase deficient). 
Both isopeptidase activity of TG2-I and transamidase activity of TG2-T mutants exhibited similar but a 
slightly smaller Ca
2+
 sensitivity compared to WT TG2 based on their EC50 values (Fig. S1). According to the 
fitted calcium sensitivity curve they reached the maximum level of activity of the wild type in each case at a 
lower calcium concentration than was needed for the wild type TG2 suggesting that their global structure is 
intact, there is no significant molecular dynamical deviance and local effects are responsible for disconnection of 
isopeptidase and transamidase activities. 
The actual pH can influence the ratio of the different type of transglutaminase reactions: deamidation 
and isopeptidase type of transglutaminase activities prefer acidic pH opposed to transamidation which favours 
alkaline pH (Fleckenstein et al. 2002; Adamczyk et al. 2013). The effect of pH was also tested on the 
isopeptidase and transamidase activities of TG2-I and TG2-T mutant enzymes, respectively, and both activities 
showed responsiveness similar to the wild type enzyme (Fig. S2) suggesting that the mutations did not influence 
catalytic steps driven by acidic-alkaline changes. 
The commercial supplier of the isopeptidase substrates suggested Tris-HCl buffer at pH 7.5 to perform 
the isopeptidase assays but during optimization of the assay increased activities were observed at acidic pH and 
therefore pH 6.8 was selected as the standard pH throughout the experiments. Some control isopeptidase 
measurements were performed in MOPS buffer which resulted in the same activity values as in experiments 
done in Tris-HCl buffer (Fig. S2) confirming the precision of the pH setting with Tris-HCl buffer.  
 
 
4. TG2-I has a higher potential to cleave γ-glutamylamine bonds than the wild type TG2 
To further characterise the effect of the W332F mutation kinetic parameters of isopeptidase reaction were 
determined using two commercially available Zedira substrates (A101: Abz-NE(Cad-Dnp)EQVSPLTLLK-OH, 
derived from N-terminal dodecapeptide of α2-plasmin inhibitor and A102: Abz-APE(Cad-Dnp)QEA-OH, 
derived from human osteonectin) to reveal the explanation of the separation of transamidase and isopeptidase 
activities (Fig. 4a and 4b). Using the A102 compound which serves as a TG2 isopeptidase assay substrate, the 
W332F mutation resulted in a similar Vmax value but the Km dropped more than 50% compared to the wild type 
enzyme. In case of the A101 compound provided as a Factor XIIIA assay substrate this mutation led to almost a 
doubled Vmax without changing the Km value which was lower than in case of the A102 substrate. These data 
suggest that the W332F mutation modifies both the substrate binding and the catalytic mechanism of 
transglutaminase reactions. 
 The affinity change towards isopeptidase substrates could be tested by the addition of different types of 
transamidase substrates as competitive inhibitors and the determination of how they influence the isopeptidase 
substrate binding. Both glutamine containing acyl donor and primary- or polyamine acyl acceptor substrates 
inhibit transamidase activity in a reversible way due to competition with the substrates. We found that the amine 
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donor biotin-cadaverine (tested up to 500 μM concentration; data not shown) and ethyl-amine did not inhibited 
the isopeptidase activity but the N-terminal α2-plasmin inhibitor peptide (PI2: NQEQVSPLTLLK; N-terminal 
dodekapeptide of α2-plasmin inhibitor; glutamine donor) inhibited it in a concentration dependent manner (Fig. 
4c and 4d). The PI2 glutamine donor peptide is the transamidase substrate form of the A101 isopeptidase 
substrate (PI2 with the γ-glutamyl cadaverine linked quencher) and based on the inhibitory curves TG2-I has a 
lower affinity for PI2 than the wild type (based on its lower inhibitory effect on TG2-I). This seems unusual 
considering that the WT and TG2-I mutant have the same affinity for this peptide in its isopeptidase substrate 
form. This feature suggests that human TG2 has a different affinity or preference toward previously 
transglutaminase modified or crosslinked proteins and both the glutamine and that the amine donor part could 
determine the efficiency of the isopeptidase activity.  
 
 
5. TG2-I has weak nucleotide binding without functional consequence 
It is known that Ca
2+
 and nucleotides regulate reciprocally transglutaminase reactions. BODIPY FL GTPγS 
binds to GTP-binding proteins following increases of fluorescence providing a non radioactive alternative tool to 
analyse protein-nucleotide interaction. The functional integrity of the mutants and the potential conformational 
changes due to the mutations were examined by their nucleotide binding (Fig. 5a). In case of the TG2-I mutant 
very weak while in case of the TG2-T mutant higher BODIPY FL GTPγS binding was observed as compared to 
the WT enzyme. The C277S and W241F mutants were used as controls because their GTP binding features have 
been already published (Murthy et al 2002; Ruan et al 2008; Gundemir and Johnson 2009); the results were 
congruent with the previously published data confirming the reliability of the assay used by us. The lower 
nucleotide binding of TG-I was similar to that of the C277S mutant. 
In spite of its weak binding to TG2-I the functional effect of the nucleotide on the isopeptidase activity 
was evident (Fig. 5b; Table S1, Fig. S3). Furthermore a significant difference has been observed in the 
nucleotide sensitivity of isopeptidase and transamidase activities; nucleotides had stronger inhibitory effect on 
the isopeptidase activity of the wild type TG2 than on its transamidase activity (Table S1). It was a surprise that 
TG2-I presented functional nucleotide sensitivity similar to the wild type TG2 despite its weak GTP binding 
while TG2-T presented slightly higher nucleotide binding affinity and accordingly higher GTP sensitivity 
compared to the wild type. One possibility is that the interaction of BODIPY-GTPγS with non canonical 
nucleotide binding sites of TG2 does not lead to the increases of its fluorescent intensity (Kiraly et al. 2009; Liu 
et al. 2002) or the slight difference between the natural and labelled nucleotides could be responsible for these 
deviances. It cannot be excluded either that the replacement of Trp
332
, similarly to Cys
277
, may break the integrity 
and balance of the highly conserved interface between the 159-173 nucleotide binding loop and the amino acids 
surrounding the active site (Murthy et al. 2002) modifying the affinity of nucleotide binding while still keeping 
its regulatory function. 
 
 
Conclusions and Perspectives 
In this study we found that the separation of different catalytic activities of transglutaminase 2 could be achieved 
by replacement of amino acids around the active site (Fig. 3) resulting in TG2 mutants which either prefer 
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isopeptidase activity or exhibit almost 6 times higher transamidase activity in a soluble phase kinetic assay. The 
characterised mutants can serve as tools to develop cellular models for better examination of biological functions 
and applications of transglutaminases. The TG2-T mutant with elevated transamidase and deficient isopeptidase 
activity can help to understand better the role of amine incorporation in cellular phenomena and may be used for 
production of covalently crosslinked biopolymers. The use of TG2-I with its high isopeptidase activity without 
transamidation potential could reveal whether crosslinking and transamidation of proteins in cells and body 
fluids are reversible or not. It could also provide a potential therapeutic tool to reverse pathological processes in 
which the increased crosslinking of proteins are in correlation with the severity of the disease manifestation as in 
neurodegenerative disorders and liver, kidney or lung fibrosis. 
Reversible covalent modification of proteins have crucial regulatory functions in cells. Protein 
phosphorylation by diverse kinases modify proteins stitching phosphate groups to Tyr, Ser or Thr residues to 
regulate many cellular phenomena and a limited number of broad specificity phosphatases are available to 
reverse this reaction. Ubiquitin ligases form isopeptide bonds between proteins and ubiquitin which can be 
reversed by deubiquitinases regulating the fates and the roles of many proteins in different cell compartments. Is 
it possible that transglutaminases can also regulate critical cellular functions by formation and breaking of 
protein-bound γ-glutamyl-linked crosslinks and amine derivatives and both of these activities reside in one 
enzyme? For example TG2 mediated covalent incorporation of biogenic amines into small GTPase plays a role 
in the activation of insulin secretion (Paulmann et al. 2009; Vowinckel et al. 2012) but it is still not clear how 
this activation is reversed. Isopeptidase activity of TG2 may remove the activating amine and similar reversible 
transglutaminase regulated system may exist where still unknown local cellular changes may lead enhanced 
transamidase, then isopeptidase activity switching on and off biochemical processes.  
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Figure legends: 
 
Fig. 1 Comparison of the isopeptidase and transamidase activities of single (a) and double (b) mutant TG2 
proteins containing Gly
224
. Isopeptidase and transamidase activities were tested using isopeptidase reaction 
substrate from Zedira (A102) and a microtiter plate method (biotin-pepT26 incorporation into immobilized 
spermine; Perez Alea M et al. 2009) in the presence of 10 and 0.5 μg enzyme, respectively. Activity is shown as 
a percentage of the activity of Gly
224
 WT TG2. Data are presented as means with ±SD from two separate 
experiments done in triplicate. The “G” in the name of the mutants means that they contain Gly at 224 amino 
acid position. 
 
Fig. 2 Comparison of the isopeptidase and transamidase activities of the selected mutant TG2 proteins 
containing Val at 224 amino acid position. Isopeptidase and transamidase activities were tested using, 
isopeptidase reaction (A102 substrate; Zedira), kinetic transamidase assay (N,N-dimethyl casein+dansyl-
cadaverine) and endpoint microtiter plate transamidase method (biotin-T26 peptide incorporation into 
immobilized spermine) in the presence of 10, 0.8, or 0.5 μg enzyme, respectively. The relative activities are 
calculated as a percentage of the activity values of the most abundant human Val
224
 containing WT TG2. Data 
are presented as means with ±SD from two or three separate experiments done in triplicate. Variants of C277S 
active site mutants did not show detectable activity in these assays (data not shown). 
 
Fig. 3 Mutagenised hydrophobic amino acids around the catalytic triad on the GDP-bound closed (a) and “open” 
form (b) of human TG2 X-ray structure (Pdb codes: 1KV3 and 2Q3Z, respectively). The replacement of these 
amino acids result in lost or significant decrease of transglutaminase activities but our data demonstrate that 
some modifications could lead to “super transglutaminases” explaining special features as biological glue or 
scissor very likely influencing physiological and pathological processes. On the grey Cα backbone of TG2 balls 
and sticks represent the catalytic triad (red; Cys277, His335, Asp358) and the mutated amino acids (grey). 
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Fig. 4 Kinetic characterisation of the isopeptidase reaction of TG2-I and WT TG2. (a, b) Determination of 
kinetic parameters for isopeptidase activity of TG2-I mutant and WT TG2 with the available commercial 
substrates A101 and A102. Data are presented as means with ±SD from three separate experiments done in 
triplicate. The data analysis and curve fitting was done by GraphPad Prism 5. (c, d) Effect of ethyl-amine and an 
α2-plasmin inhibitor derived dodecapeptide on isopeptidase activity in the presence of 50 μM. A102 substrate 
and 10 mM CaCl2. EA (ethyl-amine) was applied in 0.05, 0.2, 1.0 and 5.0 mM PI2 was applied in 0.05, 0.1, 0.5 
and 2.0 mM concentration. Data are presented as means with ±SD from two separate experiments done in 
duplicate. 
 
Fig. 5 Comparison of BODIPY-GTPγS binding of mutant and WT TG2 proteins and the inhibitory effect of 
GTPγS on the isopeptidase activity. (a) Dose response curve for TG2 enzyme amount. BODIPY-GTPγS (500 
nM) was dissolved in buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM TCEP, 1 mM MgCl2, 0.05 
% Tween-20 and 0.1 mM EGTA. The change in the fluorescence intensity (Ex/Em: 485/520 nm) was 
determined after 15 minutes of incubation. Binding is shown as a percentage of maximum binding in case of WT 
TG2. Data are presented as means with ±SD from three separate experiments done in triplicate. (b) Dose 
response curve for GTPγS on isopeptidase activity shown as a percentage of the activity of WT TG2. Different 
concentrations of GTPγS were used in presence of 1 or 10 mM CaCl2 and 10 μg of proteins. Data are presented 
as means with ±SD from two separate experiments done in triplicate. 
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The W332F and the W278F mutants have only slightly lower Ca
2+
 -sensitivity compared to the wild type TG2 
 
 
Fig. S1 Ca
2+
-dependence of isopeptidase (a) and transamidase (b) activities of the TG2-I and TG2-T mutants, 
respectively, in comparison with WT TG2 using kinetic activity assays. EC50 values based on the dose-response 
curves: Isopeptidase activity: TG2 WT EC50=0.44; TG2-I EC50=1.04; Transamidase activity: TG2 WT EC50=0.1; 
TG2-T EC50=0.96). Data are presented as means with ±SD from two separate experiments done in triplicate.  
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Optimal pH values of mutant TG2 enzymes for isopeptidase and transamidase activity 
 
 
Fig. S2 Dependence of isopeptidase and transamidase reaction rate on different pH. Kinetic MOPS buffer based 
isopeptidase (a) and Tris-HCl buffer based transamidase (b) assays were used to measure the effect of different 
pH values on isopeptidase and transamidase activities with addition of 10 or 0.83 μg wild type or mutant TG2 
enzymes, respectively. Comparison of isopeptidase activities using MOPS and Tris-HCl based buffers (c). Data 
are presented as means with ±SD from two separate experiments done in duplicate. 
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Mutation W332F influences the nucleotide binding without functional consequence 
 
 
[Nucleotide], 
μM 
Normalized isopeptidase activity (%) 
Normalized 
transamidase 
activity (%) 
TG2 
WT + 
GTPγS 
+1 mM 
Ca2+ 
TG2 
WT + 
GTPγS
+ 10 
mM 
Ca2+ 
TG2-I+ 
GTPγS
+1 mM 
Ca2+ 
TG2-I+ 
GTPγS
+ 10 
mM 
Ca2+ 
TG2 
WT + 
GTP 
+1 mM 
Ca2+ 
TG2 
WT  + 
GTP + 
10 mM 
Ca2+ 
TG2-I 
+ GTP 
+1 mM 
Ca2+ 
TG2-I + 
GTP 
+10 mM 
Ca2+ 
TG2 
WT + 
GTPγS 
+1 mM 
Ca2+ 
TG2-T 
+ 
GTPγS 
+1 mM 
Ca2+ 
0 
100.0± 
2.4 
100.0± 
1.3 
100.0± 
17.3 
100.0± 
14.7 
100.0± 
1.2 
100.0± 
9.9 
100.0± 
1.0 
100.0± 
6.2 
100.0± 
8.8 
100.0±3
.4 
2 
7.8± 
0.6 
98.5± 
2.8 
26.9± 
6.1 
112.0± 
3.2 
16.2± 
0.6 
N/D 
48.4± 
4.7 
N/D 
87.8± 
7.1 
31.1±4.
1 
5 
4.1± 
0.5 
99.5± 
3.3 
17.7± 
3.1 
111.4± 
3.7 
6.5± 
0.2 
N/D 
29.8± 
1.1 
N/D 
93.6± 
8.3 
19.1±5.
5 
20 
2.2± 
0.3 
60.0± 
6.7 
10.8± 
1.1 
62.6± 
7.4 
2.9± 
0.6 
89.1± 
1.9 
16.2± 
0.4 
111.8± 
4.9 
69.4± 
30.6 
4.7±0.6 
100 
1.9± 
0.6 
22.4± 
3.0 
9.6± 
2.0 
28.3± 
2.3 
1.7± 
0.4 
43.6± 
1.9 
9.1± 
0.1 
60.3± 
0.9 
40.8± 
2.9 
0.6±1.3 
Approximate 
IC50 values 
(μM) 
0.47 20.6 0.8 20.1 0.7 N/D 1.7 N/D 22.6 0.9 
 
 
 
Table S1 Functional effect of nucleotides on isopeptidase and transamidase activities of mutant and WT TG2 
enzymes. Table shows the dose responses for GTPγS or GTP normalized to percent of activity in the absence of 
nucleotide. Different concentrations of the nucleotides were used in the presence of 1 or 10 mM CaCl2. 
Isopeptidase or kinetic transamidase assays contained 10 or 0.83 μg of protein, respectively. Data are presented 
as means with ±SD from two separate experiments done in triplicate. The data analysis was done by GraphPad 
Prism 5. 
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Fig. S3 Graphical comparison of the inhibitory effect of nucleotides on activities of mutant and WT TG2. The 
data are listed in the Table S1. (a) Dose response for GTP and GTPγS normalized to percent of isopeptidase 
activity in the absence of nucleotides. Different concentrations of GTP or GTPγS were used in the presence of 1 
mM CaCl2 and 10 μg of protein. (b) Dose response for GTPγS normalized to percent of kinetic transamidase 
activity in the absence of nucleotide. Different concentration of GTPγS was used in the presence of 1 mM CaCl2 
and 0.5 μg of enzymes. 
 
 
 
